Solventum Corporation

$ 75.43 1.17 %

Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes. Its Dental Solutions segment provides a comprehensive range of dental and orthodontic offerings, such as brackets, clear aligners, restorative filling materials, and bonding agents. The Health Information Systems division concentrates on advanced software platforms, covering functionalities like computer-assisted physician documentation, direct billing and coding automation, classification frameworks, voice recognition capabilities, and data visualization tools. Finally, the Purification and Filtration segment supplies an array of purification and filtration technologies, including various filters, purifiers, cartridges, and specialized membranes.

CEO: Bryan C. Hanson - https://www.solventum.com

Price objectif

$84.29 11.75 %

Recommandation

Buy

DCF

$ 143.92

Loading data...

SOLV vs S&P500

Loading data...

No data available.

Quick ratio

0.75

indicates that the company may have difficulty covering its short-term debts with its readily available assets.

P/E ratio

9.23

may indicate that the company is undervalued or has poor growth prospects.

EPS

8.17

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

30.71 %

is generally considered excellent, indicating that the company is generating strong profits with its equity.

ROIC

15.87 %

generates a return higher than the cost of its capital, thereby creating value for its investors.

WACC

7.16

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

1.02

means it relies more on debt, which can increase financial risk.

Free cash flow per share

-1.17

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
6 indicates moderate financial health
Altman score
2.11 indicates an uncertain financial situation
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.17 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.36 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.